SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid community excitement and anticipation of a breakout, with many members expressing bullish sentiment using terms like "WAGMI" (We're All Gonna Make It). Some traders are eyeing a potential short squeeze, while others focus on the broader potential of the Solana ecosystem, including meme coins. There are those, however, who are concerned about potential dumps.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid renewed interest in meme stocks, sparked by a White House social media post referencing the company. The community is actively discussing potential short squeezes and reminiscing about the stock's 2021 surge, with some drawing comparisons to other trending stocks.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with many hoping for a "triple beat" and positive guidance. The community is also closely watching for potential rate cuts and any news regarding S&P 500 inclusion. Optimism is high, with some predicting a significant price surge if key resistance levels are broken.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to renewed trading momentum and discussions around its low float, with some traders speculating about a potential short squeeze. The company's recent earnings report, highlighting strong revenue growth but a net loss, is also a key point of discussion. Community members are actively debating potential price movements and trading strategies, with some expressing caution about its volatility.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around its core belief in decentralized systems and a shared vision of financial freedom on the Solana network, which is captured in its ticker name. Community members are actively sharing positive sentiment and emphasizing the project's resilience, long-term potential, and strong community, viewing it as more than just a meme coin. The discussion highlights the potential for significant growth and a strong belief in the future of Web3.

Smart Logistics Global Ltd. operates as a business-to-business contract logistics provider, specializing in industrial raw materials line-haul transportation. The company develops a smart logistics digital ecosystem for road transport by leveraging innovation, digital analytics, and infrastructure development. It enhances supply chain efficiency, shortens transit times, and improves client visibility using its integrated platform. Its services cater to a diverse range of industries including manufacturing, construction, and FMCG (Fast-Moving Consumer Goods), enabling seamless and cost-effective movement of goods across regional and national networks. The company was founded by Kwok Chiu Hue on October 8, 2020 and is headquartered in Hong Kong.

Smart Logistics Global Ltd.

Smart Logistics Global Limited Ordinary Shares

SLGB is trending due to its volatile price action and recent IPO status, with traders actively discussing potential short squeezes and price targets. Community members are also comparing it to other low-float Chinese stocks that have experienced significant gains, while some express concerns about potential manipulation. The stock's low float and recent price swings are key discussion points.

Pump.fun

$PUMP is gaining traction as community members express bullish sentiment and highlight its connection to the Pump.fun platform on the Solana blockchain. The conversation is centered around the token's potential for growth and the 'We Are All Gonna Make It' ($WAGMI) ethos. Participants are also discussing potential entries into new coins on Pump.fun

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp ($UAMY) is trending due to overnight price movement potentially linked to discussions surrounding a deal with Larvotto Resources (LRV). The community is debating whether a deal is still viable after an initial rejection, with some speculating about government intervention and the potential for dilution. Broader concerns about rare earth element trade with China are also fueling the conversation, though UAMY focuses on antimony, a critical mineral, and some see this as an overreaction to a China REE trade truce.

Keurig Dr Pepper, Inc. engages in the manufacture, marketing, distribution, and sales of non-alcoholic beverages. It operates through the following segments: U.S. Refreshment Beverages, U.S. Coffee, and International. The U.S. Refreshment Beverages segment manufactures and distributes beverage concentrates, syrups, and finished beverages including the brands Dr Pepper, Canada Dry, Mott’s, Snapple, A&W, 7UP, Sunkist soda, Squirt, Hawaiian Punch, Core Hydration, Bai, C4 Energy, Clamato, Evian, Yoo-Hoo, Big Red, and Vita Coco. The U.S. Coffee segment involves single serve brewers, specialty, hot and iced varieties, and ready-to-drink beverages. The International segment includes sales in Canada, Mexico, and other markets. The company was founded in 2018 and is headquartered in Burlington, MA.

Keurig Dr Pepper Inc

Keurig Dr Pepper is trending following Q3 earnings, with revenue exceeding expectations and a raised full-year outlook driven by coffee tariff increases. The community is discussing the potential impact of these results and future investor events. Bullish sentiment is fueled by strong sales and future growth prospects, while some analysts remain cautious due to historical performance and market conditions.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending due to news regarding a patient hospitalization which led to trading being temporarily halted, though details remain unclear, leading to speculation around trial impacts and potential buyouts. The community is actively discussing the implications of this event on NTLA and its competitors, alongside long-term prospects for gene editing and upcoming data readouts. Options traders are closely watching the stock, as indicated by LiquidTheta's actionable alerts for LEAPS contracts.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>While Dow Jones futures were up by 0.56% at the time of writing, the S&amp;P 500 futures rose 0.88%.</li><li>Asian markets ended Monday’s trading session on a positive note, with the KOSPI leading with gains of 2.5%.</li></ul>U.S. stocks appear set for a positive opening on Monday after trade tensions with China eased following a meeting with officials from the United States and China over the weekend.Treasury Secretary Scott Bessent and Trade Representative Jamieson Greer led the U.S. delegation for the fifth round of talks between the United States and China. “I think we’ve reached a substantial framework for the two leaders who will meet next Thursday,” Bessent said on ABC, following the meeting.President Donald Trump and his Chinese counterpart, President Xi Jinping, are scheduled to meet on Thursday.<h2 class="st-heading-2">Futures Trade Higher</h2>While Dow Jones futures were up by 0.56% at the time of writing, the S&amp;P 500 futures rose 0.88%, while the tech-heavy Nasdaq 100’s futures rose 1.33%. Futures of the Russell 2000 index gained 1.12%.Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) was up by 0.85% at the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ) gained 1.33% on Monday morning, and&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) rose 0.54%. Retail sentiment around the S&amp;P 500 ETF on Stocktwits was in the ‘bearish’ territory.<h2 class="st-heading-2">Asian Markets Positive</h2>Asian markets ended Monday’s trading session on a positive note, with the KOSPI leading with gains of 2.5%, followed by the Nikkei 225 index at 2.28%, and the TWSE Capitalization Weighted Stock index at 1.65%.The Shanghai Composite gained 1.17%, while the Hang Seng rose 1.01%.<h2 class="st-heading-2">Stocks To Watch</h2><ul><li>Nvidia Corp. (NVDA), Advanced Micro Devices Inc. (AMD): Shares of Nvidia and AMD rose nearly 3% in Monday’s pre-market trade amid easing trade tensions with China following the talks over the weekend.</li><li>MP Materials Corp. (MP): MP Materials shares declined nearly 5% pre-market after Bessent said he expected China to defer some of the curbs planned on rare earth exports, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/world/china/bessent-sounds-confident-note-after-trade-talks-with-china-f09d310d">report</a> by The Wall Street Journal. MP Materials is the biggest rare earth producer in the U.S.</li><li>Boeing Co. (BA): Boeing’s machinists in the St. Louis area will continue with their strike after rejecting a proposed contract for the fourth time. The Trump administration also announced that Malaysia and Cambodia will purchase some Boeing aircraft. Boeing shares were up 0.5% pre-market.</li><li>Avidity Biosciences Inc. (RNA): Avidity shares were up nearly 44% pre-market after Novartis AG (NVS) agreed to acquire the former for $12 billion.</li><li>Nucor Corp. (NUE), Bed Bath &amp; Beyond Inc. (BBBY), and NXP Semiconductors NV (NXPI) are among the companies scheduled to report their latest quarterly earnings on Monday.</li></ul>&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/goldman-sachs-risk-drawdown-rising-us-equities-new-record-highs/cLGJvJDR3tl">Goldman Sachs Warns Risks Of A Drawdown Are Rising As US Equities Climb To Fresh Record Highs: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

People walk by the New York Stock Exchange

Dow Futures Rise As China Trade Tensions Ease: NVDA, MP, BA, RNA Among Stocks To Watch

While Dow Jones futures were up by 0.56% at the time of writing, the S&P 500 futures rose 0.88%.

NVDA, MP, BA, RNA Among Stocks To Watch

Equity

<ul class="summary-bullets"><li>Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.</li><li>The deal is expected to close in the first half of 2026.</li><li>Retail sentiment toward Avidity Biosciences stock flipped to ‘extremely bullish’ by early Monday from ‘bearish’ a day ago.</li></ul>Avidity Biosciences, Inc. (RNA) shares&nbsp;soared over 43% in Monday’s early premarket session after the mid-cap biopharma focusing on developing RNA therapeutics called antibody oligonucleotide conjugates (AOC), announced a deal to be bought by Swiss pharma giant Novartis (NVS).<a href="https://stocktwits.com/symbol/RNA">Avidity Biosciences</a> stock has gained more than 60% this year.<h2 class="st-heading-2">The Novartis Deal Terms</h2>In a statement released on Sunday, Novartis said it would acquire San Diego-based Avidity Biosciences following the separation of the latter’s early-stage precision cardiology programs. The deal, approved by the boards of both companies, is valued at $72 per share in cash. This represented a 46% premium over RNA stock’s closing price of $49.15 on Friday.The total transaction value is $12 billion on a fully diluted basis. Avidity Biosciences currently boasts a market capitalization of $7.17 billion.Vas Narasimhan, CEO of Novartis, said, “Avidity’s pioneering AOC platform for RNA therapeutics ​and its late-stage assets bolster our commitment to delivering innovative, targeted, and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases.”Before the merger's closing, Avidity will transfer its early-stage precision cardiology programs and collaborations to SpinCo, a wholly owned subsidiary of Avidity. Holders of Avidity common stock will receive a distribution of one share of SpinCo for every ten shares of Avidity they hold and/or a pro rata cash distribution of the proceeds received by Avidity before the closing if certain SpinCo assets are, or SpinCo itself is, sold to a third party.The deal is expected to close in the first half of 2026, subject to the completion of a spin-off or the sale of SpinCo and other customary closing conditions, including the receipt of regulatory approvals and the approval of Avidity stockholders.Novartis said the proposed acquisition raises the expected 2024-2029 sales growth from 5% to 6% on a compounded annual growth rate (CAGR) basis, representing a significant opportunity to deliver substantial shareholder returns over time.<h2 class="st-heading-2">What Retail’s Saying About The Buyout Deal</h2>Retail sentiment toward Avidity Biosciences stock flipped to ‘extremely bullish’ by early Monday from ‘bearish’ a day ago. The message volume on the stream also improved to ‘extremely high.’&nbsp; Retail chatter spiked 6,100% over the 24 hours leading up to late Sunday.<figure class="image"><img style="aspect-ratio:620/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_27_at_6_02_00_AM_png_9d47ea362a.webp" alt="Screenshot 2025-10-27 at 6.02.00 AM.png" width="620" height="56"><figcaption>RNA sentiment and message volume as of 6 a.m. ET, Oct. 27 | source: Stocktwits</figcaption></figure>A bullish user noted that RNA traded at $5 two years ago and congratulated the believers.<stembedurl>https://stocktwits.com/Cutlass/message/633766787</stembedurl>Another user said they would cash out on Monday.<stembedurl>https://stocktwits.com/ure300/message/633760283</stembedurl>Earlier this month, Avidity Biosciences said it has completed a positive pre-Biologic License Application (BLA) meeting with the FDA regarding its delpacibart zotadirsen, an investigational drug being evaluated as a potential treatment for people living with Duchenne muscular dystrophy (DMD) who have gene mutations amenable to exon 44 skipping.&nbsp;The timing for the BLA submission was pushed back to the first quarter of 2026 from the previous guidance of year-end 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palantir-rises-premarket-today-as-stock-closes-in-on-200-psychological-threshold/cLG0TBNR3Md">Palantir Rises Premarket Today As Stock Closes In On $200 Psychological Threshold: What’s Driving The Gains?</a>

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today

Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.

Why Avidity Biosciences Stock Is Jumping Over 40% In Premarket Today

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG PR Newswire SAN DIEGO, Oct. 26, 2025 Novartis to...

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported...

Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity Biosciences to Participate in Upcoming Investor Conference Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire SAN DIEGO, Oct. 16, 2025 SAN DIEGO, Oct. 16, 2025...

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA...

Shares of Avidity Biosciences, Inc. (RNA) fell 20% in the pre-market session on Thursday after the company announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-proposed-public-offering-of-common-stock-302553124.html">stated</a> that it intends to grant the underwriters an option to purchase up to an additional $75 million of shares, while adding that there can be no assurance as to whether or when the offering may be completed.The proceeds of the offering are expected to advance the development of the company’s three late-stage clinical programs, help build appropriate commercial inventory levels to support multiple potential launches, and expand its commercial infrastructure. The company also intends to progress research and development associated with its Antibody Oligonucleotide Conjugates platform and use the proceeds for working capital and general corporate purposes.Avidity had cash, cash equivalents, and marketable securities totaling approximately $1.2 billion as of June 30. It had stated in August that it expects to have sufficient funds for its operations through mid-2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNA">RNA stock</a> rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1360/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_7_16_45_AM_png_8af84254fb.webp" alt="RNA's Sentiment Meter and Message Volume as of 7:17 a.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="1360" height="122"><figcaption>RNA's Sentiment Meter and Message Volume as of 7:17 a.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that Avidity stock has a good chance of hitting $100 in a year.<stembedurl>https://stocktwits.com/dgbio/message/628258214</stembedurl>The Financial Times <a href="https://stocktwits.com/news-articles/markets/equity/novartis-reportedly-eyeing-to-acquire-avidity-biosciences/chrSPptRd5k">reported</a> last month that Novartis made a takeover approach for Avidity, adding that the discussions were at an early stage and might not result in a deal.Avidity has three programs under development for three distinct rare diseases affecting the muscles: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD). Bank of America raised its price target on Avidity to $56 from $54 on Thursday, while maintaining a ‘Buy’ rating on the shares. The firm pinned the price target hike on recent study results, which showed that treatment with Avidity’s Del-zota reversed disease progression in patients with DMD.RNA stock is up by about 60% this year and by about 14% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-higher-ahead-of-cpi-report/chwN03BRdv4">Dow Futures Edge Higher As Wall Street Awaits Consumer Inflation Data: ORCL, OPEN, KLAR, ADBE Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is Avidity Biosciences Stock Down 20% Pre-market Today?

Avidity said on Thursday that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.

RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.

Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of -59.18% and -73.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

🚨 LIVE Earnings on Polymarket. 
Trading earnings just got much simpler: Will your favorite stock beat earnings – Yes or No?

Polymarket

Avidity Biosciences Inc

M&A Announcement

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

RNA
Avidity Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RNA News

RNAAvidity Biosciences Inc